Qol-One investigator Meeting on Rev2MDS Trial @ASH – Dec. 11 2017

By invitation only. To discus Rev2MDS (Efficacy of eltrombopag plus Lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study).

Collaboration Room Number 26 in Hall B1.